Introduction
============

Adenomyosis is a common gynecological disease; it occurs in more than 10% of the female population and the incidence is increasing. Typical symptoms include dysmenorrhea and menstrual anomalies which significantly interfere with the reproductive health and quality of life of affected women. Currently, multiple approaches are used to treat adenomyosis in clinical practice. However, all of these therapeutic options have disadvantages or limitations, such as insufficient efficacy, adverse events or high risk of recurrence. Among the different options, it has been widely recognized that hysterectomy remains the primary treatment for adenomyosis, especially for advanced-stage adenomyosis [@R9952200-1] ,  [@R9952200-2] ,  [@R9952200-3] .

The non-contraceptive benefits of levonorgestrel-releasing intrauterine system (LNG-IUS), particularly its impact on dysmenorrhea and heavy menstrual bleeding, have been proven to be effective for the management of adenomyosis in many clinical trials [@R9952200-4] ,  [@R9952200-5] ,  [@R9952200-6] . LNG-IUS can significantly and effectively alleviate the severity of dysmenorrhea in the majority of affected women. In a randomized comparative study [@R9952200-7] , quality of life was found to be considerably improved in women undergoing hysterectomy in combination with LNG-IUS at the postoperative follow-up 1 year after surgery. Saremi et al. [@R9952200-8] successfully used a novel conservative surgical procedure consisting of adenomyomectomy to treat adenomyosis and achieved relatively safe surgical outcomes, which is especially appropriate when treating women who seek to preserve their uterus and fertility.

Our research team has focused on exploring efficacious and safe treatment options for adenomyosis. Based on our previous work, we advocate an approach based on modifying and improving the clinical therapy of adenomyosis. The standard parameters used to evaluate the improved treatment include maximum thickness of the uterine muscle wall in patients with diffuse adenomyosis or maximum adenomyoma diameter in women with adenomyosis. The therapeutic options are evaluated based on these standard parameters. Based on this novel concept, our research team has proposed three individualized IUS programs for different patients, according to the severity of lesions. The design of the three IUS programs combines IUS with high-intensity focused ultrasound (HIFU), GnRH or major uterine wall resection and reconstruction of the uterus (MURU).

In one of the three IUS programs, LNG-IUS was combined with major uterine wall resection and reconstruction of the uterus (MURU) to treat women diagnosed with severe adenomyosis/adenomyoma, who had not undergone treatment with alternative therapeutic options. The current study was designed to assess the clinical efficacy and safety of this combined technique for the treatment of women diagnosed with adenomyosis, especially those with severe symptoms, and to provide evidence for the clinical application of this novel therapy.

Materials and Methods
=====================

Baseline data
-------------

Ninety patients diagnosed with adenomyosis in the Department of Gynecology, Affiliate Hospital of Maternal and Child Health Care of Zunyi Medical University between June 2012 and August 2014, based on a history of dysmenorrhea, bimanual examination, transvaginal ultrasound (TVU)/magnetic resonance imaging (MRI) and CA ~125~ levels, were recruited into this study. Patients were divided into three groups according to severity of disease, based on the maximum diameter (MD) of the adenomyoma or extent of adenomyosis (in the anterior, posterior uterine wall or fundus of the uterus) measured by TVU or MRI. Based on their MD measurements, women were classified as having mild (MD \< 35 mm), moderate (MD 35 -- 50 mm) or severe disease (MD \> 50 mm). The study procedures were approved by the ethics committee of Zunyi Medical University. Written informed consent was obtained from all participants.

Inclusion and exclusion criteria
--------------------------------

Patients with severe (MD \> 50 mm) and moderate disease (MD 35 -- 50 mm) who had not been treated with HIFU or had refused HIFU were included in this study. Patients with mild disease (MD \< 35 mm) who wished to retain their fertility and patients for whom surgery was contraindicated were excluded from the study.

MURU combined with LNG-IUS
--------------------------

Conventional laparotomy was performed under general anesthesia, starting with a 5 -- 7 cm transverse incision of the lower abdomen. A towel clamp was used to hold the uterine body and pull it out of the abdominal wall. Adhesions were separated when necessary. The uterine vessels were ligated close to the isthmus using a tourniquet. The myometrium was longitudinally incised along the midline of the uterine fundus to the bottom of uterine cavity, approximately 0.5 -- 1 cm under the uterine serosa. The myometrium was split and separated downward to the superior border of the uterine isthmus (exterior incision). Subsequently, the myometrium (interior incision) was separated downward to the isthmus approximately 0.5 -- 1 cm from the endometrium. The exterior and interior incisions were converged in the uterine isthmus when the uterus became the pyriform shape. A large part of the myometrial tissue between the exterior and interior incisions and above the isthmus was resected. Redundant uterine tissue in the seromuscular and mucous layers was resected. The LNG-IUS tail filament was approximately 3 -- 4 cm long, and a knot was tied at the end. The redundant wire of the IUS was removed. The IUS was inserted into the uterine cavity, the uterine mucosa was sutured with 2/0 absorbable sutures to reconstruct the uterine cavity, and bilateral seromuscle were pulled to the center line and sutured using 2/0 absorbable interrupted sutures to create a new uterus. The tourniquet was removed when bleeding had stopped. The abdominal cavity was washed and sutured layer by layer. A drainage tube was placed where necessary.

Requirements for uterine reconstruction
---------------------------------------

The uterine cavity had to be reconstructed in such a manner that it would be capable of holding an IUS or a slightly larger device. The aim was also to ensure that the thickness of the myometrial layer after uterine cavity reconstruction was less than 30 mm and that the uterine volume would be the same or even slightly smaller than that of similar women of childbearing age [@R9952200-9] . Uterine volume was calculated according to the formula: V = π/6 × a × b × c (V refers to the uterine volume; a, b and c denote the uterine length, width and thickness measured by ultrasound, respectively) [@R9952200-10] .

Weight and volume of excised muscle tissue
------------------------------------------

All excised muscle tissues were weighed. To measure the volume of resected tissue, all resected muscle tissues were placed in a beaker filled with water. The volume of the outflow was equal to the volume of the excised muscle tissue. The excised muscle tissues were then prepared for histopathological examination.

Evaluation of clinical efficacy and safety
------------------------------------------

The operation time, intraoperative blood loss, postoperative complications and the length of hospital stay were used to evaluate the safety of the procedure. At 3, 6 and 12 months postoperatively, patients were followed up and the following parameters were evaluated: symptoms of dysmenorrhea, menstrual blood volume, uterine volume (measured by TVU or MRI) and serum CA 125 levels. The extent of dysmenorrhea was evaluated using a visual analogue scale (VAS) [@R9952200-11] . Menstrual blood volume was estimated using the Sensation Quantity Scale (SQS), with values obtained from patients who self-estimated the changes in menstrual volume before and after surgery. Reported volumes ranged from extensive to zero (amenorrhea). The SQS was divided into six degrees as follows: very large amount, large amount, moderate amount, small amount, very slight amount and zero, and were represented by a corresponding score of 5, 4, 3, 2, 1 and 0 points, respectively.

Statistical analysis
--------------------

All data analyses were performed using the SPSS 17.0 statistical software package (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± standard deviation (SD). The differences between two groups were compared using Studentʼs t-test. A p value of less than 0.05 was considered statistically significant.

Results
=======

Baseline characteristics
------------------------

A total of 90 patients who met the inclusion criteria were enrolled in this study. Of these patients, 37 cases were classified as having a moderate adenomyosis and 53 women were classed as having severe adenomyosis. All patients manifested varying degrees of dysmenorrhea and increasing menstrual blood volumes preoperatively, especially patients with moderate and severe adenomyoma. The preoperative mean VAS and SQS scores were calculated as 6.3 ± 3.3 and 4.2 ± 0.4, as shown in [Table 1](#TB9952200-1){ref-type="table"} .

###### 

**Table 1**  Baseline characteristics of the enrolled patients (n = 90).

  Variable               
  ---------------------- -----------------------
  Moderate adenomyosis   n = 37
  Severe adenomyosis     n = 53
  Mean age               39.67 ± 10.31 (years)
  Mean VAS               6.3 ± 3.3
  Mean SQS               4.2 ± 0.4

Clinical efficacy of MURU combined with LNG-IUS
-----------------------------------------------

Prior to surgery, the average uterine volume was 273.7 ± 109.7 cm ^3^ in all 90 patients. The average weight of removed uterine muscle tissue was 329.1 ± 189.6 g, approximately 5.49 times that of a normal uterine weight of 60 g (p \< 0.05). At postoperative 3 months, the average uterine volume was 58.9 ± 18.6 cm ^3^ . At postoperative follow-up, the uterine volume was slightly smaller than that of a normal uterus. The procedures used for MURU combined with LNG-IUS are shown in [Fig. 1](#FI9952200-1){ref-type="fig"} .

![ Surgical procedure of MURU + LNG-IUS. **a**  The myometrium was incised and separated at 0.5 -- 1 cm beneath the serosa downward to the superior border of isthmus bilaterally; **b**  LNG-IUS is placed in the uterine cavity; **c**  The uterine cavity is reconstructed; **d**  The uterus is completely reconstructed.](10-1055-a-0995-2200-igf01ad){#FI9952200-1}

Safety of MURU Combined with LNG-IUS
====================================

MURU combined with LNG-IUS was successfully performed in all 90 women. The average operation time was 82.4 ± 13.8 min and the mean intraoperative blood loss was 53.3 ± 20.3 ml. Postoperatively, slight incisional fat degeneration occurred in three patients, which recurred soon after anti-inflammatory therapy. The average length of hospital stay was 4.3 ± 0.8 days. No complications occurred during surgery or the postoperative period in any patients. The pathological examination of the excised uterine tissues confirmed the diagnosis of adenomyosis in all patients.

Postoperative Complications
===========================

At 3 months after surgery, the incidence of amenorrhea, oligomenorrhea and slight menstruation was 38.9% (n = 35), 53.33% (n = 48) and 7.78% (n = 7), respectively. Symptoms of dysmenorrhea had disappeared completely. Serum CA 125 levels had decreased to normal ranges. TVU/MRI showed that the uterine size and morphology had been restored to normal ranges ( [Table 2](#TB9952200-2){ref-type="table"} ,  [Figs. 2](#FI9952200-2){ref-type="fig"} and [3](#FI9952200-3){ref-type="fig"} ).

###### 

**Table 2**  Comparison of different parameters before and after MURU combined with LNG-IUS (n = 90).

                Preoperative    Postoperative                   
  ------------- --------------- --------------- --------------- ---------------
  VAS           6.3 ± 3.3       0.0\*           0.0\*           0.0\*
  SQS           4.2 ± 0.4       0.5 ± 0.3\*     0.4 ± 0.2\*     0.7 ± 0.4\*
  V (cm ^3^ )   273.7 ± 109.7   58.9 ± 18.6\*   52.9 ± 11.9\*   59.9 ± 12.5\*
  CA 125        89.7 ± 74.7     13.8 ± 7.8\*    14.7 ± 6.7\*    11.6 ± 6.7\*

![ Ultrasound of a case with severe uterine adenomyosis. **a**  Preoperative ultrasound of severe uterine adenomyosis, uterine size: 12.80 × 8.54 × 9.59 cm ^3^ ; **b**  Ultrasound of severe uterine adenomyosis at 3 months postoperatively, uterine size: 5.61 × 4.30 × 6.42 cm ^3^ .](10-1055-a-0995-2200-igf02ab){#FI9952200-2}

![ MRI of a case with severe uterine adenomyosis. **a**  Preoperative MRI image of severe adenomyosis; **b**  MRI image of severe adenomyosis at 3 months postoperatively.](10-1055-a-0995-2200-igf03ab){#FI9952200-3}

Discussion
==========

Adenomyosis is most commonly diagnosed in middle-aged women. Complete removal of adenomyoma lesions during surgery can decrease the risk of recurrence and create a favorable uterine environment for pregnancy [@R9952200-8] . MURU combined with LNG-IUS can be used to entirely resect lesions in patients with adenomyosis. In this study, MURU was a novel approach to treat women with adenomyosis wishing to preserve their fertility. Consequently, the safety of the MURU procedure was the top priority. All patients were successfully treated by MURU combined with IUS. Three patients had mild incisional fat degeneration after surgery; no other complications occurred during or after surgery, suggesting that MURU combined with IUS implantation is a safe procedure to treat adenomyosis. During postoperative follow-up, symptoms of dysmenorrhea completely disappeared and serum CA 125 levels decreased to normal ranges in all patients. No postoperative recurrence was observed. These favorable outcomes validate the clinical efficacy of this combined technique.

Adenomyosis manifests as dysmenorrhea and increased menstrual volume. Repeated bleeding and fibrosis of the ectopic lesions contribute to dysmenorrhea. The main reason for the increase in menstrual volume is thickening of the endometrium and weakening of the myometrium. Dysmenorrhea and hemorrhage are generally positively correlated with lesion size and severity of disease, with adenomyosis symptoms often correlated with the course of disease. Patients with severe adenomyosis frequently manifest with significant dysmenorrhea and hemorrhage. After combined treatment consisting of MURU and LNG-IUS, the symptoms of dysmenorrhea disappeared completely and menstrual volume was significantly reduced in all patients. A large number of myometrium lesions was removed and the uterine cavity was significantly reduced after MURU. LNG-IUS has been proven to reduce menstrual volumes or even lead to amenorrhea and has therefore been used to treat mild adenomyosis [@R9952200-12] ,  [@R9952200-13] . The removal of lesions and placement of LNG-IUS can collectively mitigate the symptoms of hypermenorrhea and dysmenorrhea.

Therapeutic options for adenomyosis can be divided into conservative and surgical approaches. Conservative approaches such as medication and physiotherapy treat adenomyosis while preserving the uterus. The standard surgical option is hysterectomy. Both methods have their respective limitations, including low clinical efficacy, adverse events, high cost and high rate of recurrence. [@R9952200-14] . HIFU treatment can achieve therapeutic benefits in certain patients [@R9952200-15] , but it does not adequately treat diffuse adenomyosis affecting the whole myometrium. In addition, HIFU equipment is very expensive. Conservative surgical options, such as uterine artery embolization (UAE), transcervical resection of the endometrium (TCRE) and lesion resection also have their limitations, especially when treating patients with severe adenomyosis [@R9952200-16] ,  [@R9952200-17] ,  [@R9952200-18] ,  [@R9952200-19] .

Hysterectomy remains the main treatment for severe adenomyosis. Although adenomyosis can be treated by hysterectomy, this approach can still result in adverse events or even recurrence [@R9952200-20] ,  [@R9952200-21] . Most patients diagnosed with adenomyosis want to preserve their uterus [@R9952200-9] ,  [@R9952200-22] . Hysterectomy can lead to pelvic floor dysfunction, premature ovarian failure, affective disorder and family problems [@R9952200-23] ,  [@R9952200-24] ,  [@R9952200-25] . In addition to the traditional approach consisting of lesion resection, Nishida et al. have also described a novel type of surgery to treat diffuse adenomyosis [@R9952200-26] . However, their approach is limited to excising part of the muscle wall. With MURU, all of the myometrium between the serosa (interior 0.5 -- 1 cm) and endometrium (exterior 0.5 -- 1 cm) and above the uterine isthmus is resected. Moreover, the enlarged uterine cavity is reduced to a diameter of 3 -- 4 cm. MURU therefore differs significantly from the localized excision approach proposed by Nishida. Although MURU has been used to treat severe adenomyosis, the use of this procedure is still in its exploratory stages and will need to be further improved with experience and changes to surgical standards. When we used this novel approach in our study, we noted the following items which could improve outcomes after MURU. Firstly, the residual myometrial tissue on the serosa and endometrium side should be less than 1 cm during surgery. Secondly, the volume of the uterine cavity should be reduced until it is able to contain one LNG-IUS or a slightly larger device. Thirdly, the excess muscle tissue should be removed before suturing the serosa and mucous layers to ensure that fewer lesions are left after uterine reconstruction. Fourthly, it is very important to pay attention to complete suture and prevent uterine bleeding. In addition, ligature of the uterine artery on both sides of the uterus should be avoided, especially adjacent to the lower uterine segment. Intraoperatively, electric knife should be maintained at an appropriate distance from the uterine, it might destroy the residual lesions. Symmetry and aesthetics should be considered during uterine reconstruction. The postoperative size and appearance of the reconstructed uterus should resemble that of a normal uterus.

In recent years, LNG-IUS, a novel method for long-acting contraception, has begun to be used for non-contraceptive purposes. LNG-IUS can prevent the growth and recurrence of endometriosis lesions after the IUS is placed in the uterine cavity. LNG-IUS has also been found to be highly efficacious to treat mild adenomyosis [@R9952200-27] . A highly effective progestin, levonorgestrel can maintain high concentrations in the endometrium and has a long-lasting impact which can change aberrant endometrium to a more normal state [@R9952200-28] . Transforming the source of endometriosis is the basic approach favored by proponents of ectopic endometrium determinism [@R9952200-29] . IUS can partly prevent the recurrence of endometriosis.

The placement of an IUS into the uterus can significantly reduce lesion sizes in women with mild adenomyosis [@R9952200-30] . The underlying mechanism is still largely unknown, probably because levonorgestrel shrinks ectopic lesions in the myometrium, which are then absorbed by the body. However, these effects have not been observed in patients with severe adenomyosis, possibly because the effective component (levonorgestrel) of IUS is mainly released in the vicinity of the endometrium rather than the myometrium [@R9952200-31] . In this study, most lesions were excised by MURU, and the uterine wall became thinner after surgery (≤ 30 mm), which promoted the effect of IUS. Although a large number of lesions were excised, MURU still significantly differs from hysterectomy. Theoretically, it is impossible to completely remove all residual lesions with MURU. MURU should therefore be supplemented by simple and efficient measures to prevent recurrence. LNG-IUS resolves this problem.

Conclusion
==========

MURU can be used to excise adenomyosis lesions while preserving the uterus. LNG-IUS has a beneficial effect on mild adenomyosis and can help to prevent recurrence. Consequently, MURU combined with LNG-IUS is an efficacious and safe treatment for severe adenomyosis. Moreover, it is convenient and requires no special equipment, meaning that the combined procedure can be carried out in multi-level hospitals. Nevertheless, this novel technique is still in its early stages, and the long-term efficacy and safety remain to be elucidated. In addition, the impact on uterine hemodynamics and ovarian function is largely unknown and urgently requires further study.
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